CA2695259C - Metabolites and derivatives of ambrisentan - Google Patents

Metabolites and derivatives of ambrisentan Download PDF

Info

Publication number
CA2695259C
CA2695259C CA2695259A CA2695259A CA2695259C CA 2695259 C CA2695259 C CA 2695259C CA 2695259 A CA2695259 A CA 2695259A CA 2695259 A CA2695259 A CA 2695259A CA 2695259 C CA2695259 C CA 2695259C
Authority
CA
Canada
Prior art keywords
ambrisentan
metabolites
compounds
metabolite
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2695259A
Other languages
English (en)
French (fr)
Other versions
CA2695259A1 (en
Inventor
Lawrence S. Melvin, Jr.
Martina Ullrich
Hans-Guenther Hege
Juergen Weymann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Royalty Pharma Collection Trust
Original Assignee
Gilead Sciences Inc
Royalty Pharma Collection Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, Royalty Pharma Collection Trust filed Critical Gilead Sciences Inc
Publication of CA2695259A1 publication Critical patent/CA2695259A1/en
Application granted granted Critical
Publication of CA2695259C publication Critical patent/CA2695259C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/145555—Hetero-N
    • Y10T436/147777—Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2695259A 2007-07-31 2008-07-31 Metabolites and derivatives of ambrisentan Active CA2695259C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95305307P 2007-07-31 2007-07-31
US60/953,053 2007-07-31
PCT/US2008/009236 WO2009017777A2 (en) 2007-07-31 2008-07-31 Metabolites and derivatives of ambrisentan

Publications (2)

Publication Number Publication Date
CA2695259A1 CA2695259A1 (en) 2009-02-05
CA2695259C true CA2695259C (en) 2016-05-24

Family

ID=39924953

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2695259A Active CA2695259C (en) 2007-07-31 2008-07-31 Metabolites and derivatives of ambrisentan

Country Status (8)

Country Link
US (1) US8217155B2 (enExample)
EP (1) EP2183223A2 (enExample)
JP (1) JP2010535210A (enExample)
CN (1) CN101801936B (enExample)
AU (1) AU2008282773B8 (enExample)
CA (1) CA2695259C (enExample)
MX (1) MX2010001255A (enExample)
WO (1) WO2009017777A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
PL2101777T3 (pl) 2006-12-12 2015-10-30 Gilead Sciences Inc Kompozycja do leczenia nadciśnienia płucnego
JP2010535210A (ja) 2007-07-31 2010-11-18 ギリード・コロラド・インコーポレーテッド アンブリセンタンの代謝産物および誘導体
US9255931B2 (en) 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
DK2637664T3 (en) 2010-10-15 2017-06-19 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR TREATMENT OF PULMONAL HYPERTENSION
CN102276536B (zh) 2011-06-10 2015-04-29 中国科学院化学研究所 一种光学纯的(+)-安倍生坦和光学纯的(+)-达芦生坦的制备方法
CN103012281B (zh) * 2011-09-22 2015-04-08 江苏康缘药业股份有限公司 一种手性2-[(4,6-二甲基嘧啶-2-基)氧基]-3-甲氧基-3,3-二苯基丙酸的消旋化方法
CN104280480B (zh) * 2013-07-02 2016-12-28 天津药物研究院有限公司 一种分离检测安立生坦及其有关物质的方法
CN104515816B (zh) * 2013-09-29 2016-04-20 天津药物研究院 一种安立生坦原料及制剂有关物质的检测方法
CN104359993B (zh) * 2014-12-09 2016-03-30 江苏康缘药业股份有限公司 一种安立生坦有关物质的检测方法
EP3235496A1 (en) * 2016-04-19 2017-10-25 Noorik Biopharmaceuticals AG Treatment of acute renal failure
KR20230015874A (ko) 2019-12-17 2023-01-31 치누크 세라퓨틱스, 인크. 아트라센탄에 의해 iga 신장병증을 치료하는 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19726146A1 (de) 1997-06-19 1998-12-24 Basf Ag Neue ß-Amino und ß-Azidopcarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten
DE19806438A1 (de) 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
PA8652001A1 (es) * 2004-11-05 2006-10-13 Wyeth Corp Metabolitos glucuronidos de tigeciclina y epimeros de los mismos
US20090131441A1 (en) * 2005-01-25 2009-05-21 Dompe Phar.R.Ma S.P.A. Metabolites Of 2-Arylpropionic Acid Derivatives And Pharmaceutical Compositions Containing Them
JP2008528627A (ja) * 2005-01-31 2008-07-31 マイラン ラボラトリーズ インク． グルクロン酸化されたネビボロール代謝産物
EP1891041A1 (en) * 2005-06-17 2008-02-27 Pfizer Products Incorporated METABOLITES OF 1- [-6- (1-ETHYL-l-HYDROXY-PROPYL) -PYRIDIN-3-YL]-3- [2- (4-METHYL-PIPERAZIN-I-YL) -BENZYL]-PYRR0LIDIN-2-0NE AS SERATONIN RECEPTOR ANTAGONISTS
PL2101777T3 (pl) 2006-12-12 2015-10-30 Gilead Sciences Inc Kompozycja do leczenia nadciśnienia płucnego
CA2669535A1 (en) 2006-12-12 2008-06-19 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorders
JP2010535210A (ja) 2007-07-31 2010-11-18 ギリード・コロラド・インコーポレーテッド アンブリセンタンの代謝産物および誘導体
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
WO2010062640A1 (en) 2008-10-28 2010-06-03 Gilead Colorado, Inc. Methods for treating idiopathic pulmonary fibrosis and associated complications

Also Published As

Publication number Publication date
US20100204163A1 (en) 2010-08-12
WO2009017777A3 (en) 2009-04-09
CN101801936A (zh) 2010-08-11
EP2183223A2 (en) 2010-05-12
AU2008282773A1 (en) 2009-02-05
AU2008282773B2 (en) 2012-11-08
MX2010001255A (es) 2010-12-06
AU2008282773B8 (en) 2013-03-07
CN101801936B (zh) 2012-10-03
JP2010535210A (ja) 2010-11-18
US8217155B2 (en) 2012-07-10
WO2009017777A2 (en) 2009-02-05
CA2695259A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
AU2008282773B8 (en) Metabolites and derivatives of ambrisentan
Lee et al. Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione
CN116120315B (zh) 一种kras g12c抑制剂及其应用
EP3822272A1 (en) Fused tri-cyclic compound as pde3/pde4 dual inhibitor
CN111902417B (zh) 一种二芳基巨环化合物、药物组合物以及其用途
US20210292304A1 (en) Deuterated mgl-3196 compound and use thereof
CN110092779B (zh) 一种取代的苯基化合物及其应用
EP3689875A1 (en) Use of triazolopyrimidine, triazolopyridine compounds and composition thereof for treating prc2-mediated diseases
EP4223751A1 (en) Benzamide compound and use thereof
TW202328111A (zh) 內皮素ａ（ｅｔａ）受體拮抗劑化合物、其藥物組合物及其用途
He et al. Discovery, synthesis and evaluation of novel reversible monoacylglycerol lipase radioligands bearing a morpholine-3-one scaffold
WO2023028091A1 (en) Deuterated empathogens
CN120344525A (zh) 一种甲状腺激素β受体激动剂、晶型、制备方法和用途
RU2535975C2 (ru) Производные изатина для применения в качестве агентов визуализации in vivo
Urabe et al. Discovery of MGS0274, an ester prodrug of a metabotropic glutamate receptor 2/3 agonist with improved oral bioavailability
US10633351B2 (en) Halogenated compound and axially chiral isomer thereof
CN110003291B (zh) 一种氟代糖基修饰的紫杉醇类化合物及其合成方法和应用
EP4741391A1 (en) Nmt inhibitor, and preparation method therefor and use thereof
Cavalluzzi et al. First synthesis and full characterization of mexiletine N-carbonyloxy β-D-glucuronide
US12221432B2 (en) Estrogen receptor antagonist
WO2021169769A1 (zh) 芳香族化合物及其药物组合物和用途
US20260035349A1 (en) 3,4-alkoxy Substituted Phenethyl Lactam Compound, Preparation Method therefor, and Use Thereof
RU2827863C2 (ru) Конденсированное трициклическое соединение в качестве двойного ингибитора pde3/pde4
CN113582971B (zh) 一种小分子免疫抑制剂、其制备方法及其应用
JP2025534771A (ja) Ｔｙｋ２阻害剤としての複素環式化合物及び合成及び応用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130726

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250610

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250610